Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) plummeted as much as 11.69% in pre-market trading on Wednesday, October 31, 2024, after the biopharmaceutical company announced a potential $100 million common stock offering.
The stock sell-off came despite Travere reporting solid third-quarter 2024 financial results earlier in the day. The company's quarterly earnings per share of -$0.70 met analysts' consensus estimates, while revenue of $62.9 million beat expectations of $59.7 million, driven by a 69.56% year-over-year increase.
However, investors appeared to be more focused on the company's plans to raise additional capital through a stock sale. Issuing new shares typically dilutes the ownership stake of existing shareholders, which can put downward pressure on the stock price in the near term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.